Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingming Yang

Showing results (251-260 of 273) with videos related to

Pageof 28
Sort By:
European Journal of Heart Failure|March 2, 2026
Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
European Journal of Heart Failure|September 29, 2023
Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Toru Kondo, Mingming Yang, et al.
European Journal of Heart Failure|March 2, 2026
Mitral regurgitation in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
Nature Communications|March 22, 2020
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunityChristina A von Roemeling, Yifan Wang, Yaqing Qie, et al.
JAMA Cardiology|August 13, 2025
Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical TrialMisato Chimura, Pardeep S Jhund, Alasdair D Henderson, et al.
JACC. Heart Failure|February 5, 2025
EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVERMingming Yang, Toru Kondo, Atefeh Talebi, et al.
Journal of the American Heart Association|December 24, 2024
Clinical Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction and With Reduced Ejection Fraction According to the Prognostic Nutritional Index: Findings From PARADIGM-HF and PARAGON-HFSimone Solano, Mingming Yang, Paolo Tolomeo, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 21, 2025
Sacubitril/valsartan and Quality of Life Assessed Using the EuroQol 5-Dimension 3-Level Questionnaire Level Sum Score (EQ-5D-3L-LSS) in Patients with HFrEF and HFmrEF/HFpEFMingming Yang, Alasdair D Henderson, Inder S Anand, et al.
European Journal of Heart Failure|August 22, 2024
Clinical characteristics and outcomes of patients aged 80 years and over with heart failure: Need for better treatmentMingming Yang, Toru Kondo, Inder S Anand, et al.
JACC. Asia|February 19, 2024
Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER TrialXiaowen Wang, Carolyn S P Lam, Muthiah Vaduganathan, et al.
Pageof 28

Showing results (251-260 of 273) with videos related to

Sort By:
Pageof 28
European Journal of Heart Failure|March 2, 2026
Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
European Journal of Heart Failure|September 29, 2023
Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Toru Kondo, Mingming Yang, et al.
European Journal of Heart Failure|March 2, 2026
Mitral regurgitation in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
Nature Communications|March 22, 2020
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunityChristina A von Roemeling, Yifan Wang, Yaqing Qie, et al.
JAMA Cardiology|August 13, 2025
Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical TrialMisato Chimura, Pardeep S Jhund, Alasdair D Henderson, et al.
JACC. Heart Failure|February 5, 2025
EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVERMingming Yang, Toru Kondo, Atefeh Talebi, et al.
Journal of the American Heart Association|December 24, 2024
Clinical Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction and With Reduced Ejection Fraction According to the Prognostic Nutritional Index: Findings From PARADIGM-HF and PARAGON-HFSimone Solano, Mingming Yang, Paolo Tolomeo, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 21, 2025
Sacubitril/valsartan and Quality of Life Assessed Using the EuroQol 5-Dimension 3-Level Questionnaire Level Sum Score (EQ-5D-3L-LSS) in Patients with HFrEF and HFmrEF/HFpEFMingming Yang, Alasdair D Henderson, Inder S Anand, et al.
European Journal of Heart Failure|August 22, 2024
Clinical characteristics and outcomes of patients aged 80 years and over with heart failure: Need for better treatmentMingming Yang, Toru Kondo, Inder S Anand, et al.
JACC. Asia|February 19, 2024
Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER TrialXiaowen Wang, Carolyn S P Lam, Muthiah Vaduganathan, et al.
Pageof 28